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Abstract 
Massive upper gastrointestinal bleeding due to malignancy is relatively uncommon and 
the duodenum is the least frequently involved site. Duodenal metastasis is rare in renal 
cell carcinoma (RCC) and early detection, especially in case of a solitary mass, helps in 
planning further therapy. We report a case of intractable upper gastrointestinal bleeding 
from metastatic RCC to the duodenum. The patient presented with melena and anemia, 
13 years after nephrectomy for RCC. On esophagogastroduodenoscopy, a submucosal 
mass was noted in the duodenum, biopsies of which revealed metastatic RCC. In 
conclusion, metastasis from RCC should be considered in nephrectomized patients 
presenting with gastrointestinal symptoms and a complete evaluation, especially 
endoscopic examination followed by biopsy, is suggested. 
Introduction 
Renal cell carcinoma (RCC) has a potential to metastasize to almost any site. In 
descending order of frequency, the most common sites of metastasis are the lung, lymph 
nodes, liver, bones, adrenal glands, kidneys, brain, heart, spleen, intestine, and skin [1]. It 
can involve any part of the bowel and accounts for 7.1% of all metastatic tumors to the 
small intestine [2]. Duodenal metastasis from RCC is very uncommon and only few cases 
have been described in the literature (table 1). Also duodenal metastasis generally occurs 
when there is widespread nodal and visceral involvement and evidence of metastatic 
disease elsewhere in the body. Commonly, renal cell metastases present many years after 
initial treatment, with recurrences reported up to 17.5 years after initial surgery [3]. Most 
cases of duodenal metastasis from RCC present with upper gastrointestinal bleeding or 
obstructive symptoms, and sequelae may include anemia, melena, fatigue, and early 
satiety. Several treatments of solitary RCC metastasis have been reported. These include a 
variety of surgical and interventional therapy options that have been shown to provide  
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effective survival benefits. Here we report on a patient with solitary duodenal metastasis 
who presented with gastrointestinal bleeding 13 years after nephrectomy. 
Case Report 
A 66-year-old male presented with progressively worsening shortness of breath, fatigue and 
generalized weakness for the last 3 weeks. He reported black tarry stools for about 3–4 days prior to 
admission. He also complained of loss of appetite and 15 pounds unintentional weight loss over the last 
few weeks. He denied nausea, vomiting, or abdominal pain. There was no history of recent use of 
nonsteroidal antiinflammatory drugs. His past medical history was significant for hypertension, 
bilateral RCC status post right nephrectomy and partial left nephrectomy done 13 years earlier, 
ileocolectomy for perforated cecal diverticulitis, and prostate cancer treated with radiation. He had a 
50 pack year history of smoking, but denied any alcohol use. On physical exam, he was orthostatic and 
appeared pale. Pertinent physical findings included melanotic stools. Abdominal examination was 
unremarkable. No signs of chronic liver disease were noted. 
Laboratory investigations on admission were significant for microcytic hypochromic anemia with 
hemoglobin 5 g/dl, hematocrit 16.8%, MCV 72 fl and MCH 21.7 pg/l. Liver enzymes were within 
normal range. Esophagogastroduodenoscopy showed an actively bleeding, 4 cm irregular, polypoid, 
ulcerative mass in the second portion of the duodenum, adjacent to but not involving the papilla 
(fig. 1). Biopsies were obtained from this mass, following which the patient started having severe 
bleeding from the lesion. Endoscopic interventions to control the bleeding were unsuccessful. Visceral 
angiography was done which demonstrated no extravasation or pseudoaneurysm in the duodenal 
vascular distribution or pancreaticoduodenal arcade. However, empiric angiographic embolization of 
the gastroduodenal artery was performed. Despite these endoscopic and radiologic embolization 
attempts, bleeding continued, requiring another endoscopic procedure when the lesion was treated with 
argon plasma coagulation with successful control of the bleeding. The patient received a total 
transfusion of 11 units of packed red blood cells during his hospital course. Histopathology of the 
biopsies from the duodenal mass during endoscopy revealed metastatic RCC.  
Further investigations included a computed tomography scan of the abdomen which showed an 
ill-defined mass measuring 5.4 × 3.3 cm at the junction of the second and third portion of the 
duodenum, adjacent to but not involving the head of the pancreas (fig. 2). There was no evidence of 
liver or visceral metastasis, and the visceral vessels and lymph nodes appeared normal. Ultrasound of 
the abdomen showed normal pancreaticobiliary system with no common bile duct dilatation suggestive 
of obstruction. 
Subsequently, the patient underwent exploratory laparotomy which revealed a 7 × 4 cm mass in 
the second portion of the duodenum. There was no evidence of malignant ascites, carcinomatosis, 
omental implants, or involvement of the pancreas or liver. He underwent pylorus-sparing 
pancreaticoduodenectomy, choledochojejunostomy, handsewn pancreaticojejunostomy and 
gastrojejunostomy with removal of the mass. Biopsies from the mass during endoscopy and surgical 
pathology were consistent with RCC. Postoperatively, the patient’s hospital course was complicated by 
leakage of the pancreaticojejunostomy fistula and sepsis, and he died two weeks later. 
Gross examination of the surgical specimen revealed a 2.0 × 1.5 × 0.8 cm tan-red polypoid, 
pedunculated tumor protruding into the duodenum approximately 0.5 cm away from the ampulla of 
Vater. The tumor appeared confined grossly to the mucosa and submucosa of the duodenum and did 
not appear to extend into or through the muscularis. There was no involvement of the pancreas. Eight 
lymph nodes were identified in the resection specimen, and all were negative for metastatic tumor with 
successful excision of all involved structures with clear margins and with no lymph node involvement.  
Microscopically, the tumor was composed of clear cells arranged in a trabecular and alveolar pattern 
(fig. 3). Immunohistochemically the tumor was positive for vimentin, CD10, AE1/AE3 and epithelial 
membrane antigen and negative for CK7, CK20 and PNRA (fig. 4). Histopathological features and 
immunostaining findings were compatible with a diagnosis of metastatic RCC of clear cell type.  
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Discussion 
Gastrointestinal tract metastases are a rare cause of massive gastrointestinal bleeding. 
Small bowel involvement by metastatic tumors is rare and has been reported in only 1–2% 
of autopsy cases [2, 4]. Common metastatic malignancies known to involve the small 
bowel are melanomas, lung cancer, cervical carcinomas, RCCs, thyroid carcinomas, 
hepatomas and Merkel cell carcinomas. RCC metastases account for 7.1% of these lesions 
[2]. Graham reported that only 4% of RCCs metastasized to the small intestine [5]. 
Solitary duodenal metastasis from RCC is exceedingly rare and most frequently involves 
the periampullary region or the duodenal bulb [6, 7]. 
We have summarized the reported cases of duodenal metastasis from RCC in table 1. 
We have included patients with the bulk of the gross tumor in the duodenal or ampullary 
regions, distinct from pancreatic involvement. The majority of patients were found to 
have metastasis within 1 year after nephrectomy though it could be seen even after several 
years [8]. The mean duration post nephrectomy to diagnosis of these solitary duodenal 
metastases was 7.9 ± 4.7 years (median 8 years). The range was 0 to 13 years, with one 
patient presenting with a synchronous metastasis. Males were more commonly affected 
(male:female ratio 3:1) and the incidence of metastasis increased with age [7]. Mean age 
at diagnosis of duodenal metastasis was 60.7 ± 14 years (median age 63 years, range  
16–86 years). 
The natural history of RCC is unpredictable. Disease eradication and cure are possible 
after nephrectomy; however, there is also the possibility of a long period of disease 
latency, followed by recurrence of metastatic disease at unsuspected anatomic locations. 
RCC can metastasize via the lymphatic or hematogenous route, as well as by peritoneal 
dissemination or direct invasion into adjacent anatomic structures [8]. The duodenum is 
an exceptionally rare site of metastasis in RCC, which is perhaps counterintuitive given its 
retroperitoneal proximity to the right kidney, though a majority (around 70%) occur from 
the right kidney. 
The most common clinical presentation of gastrointestinal metastases of RCC is 
gastrointestinal bleeding, resulting from the invasion of intestinal vessels by the neoplastic 
disease and/or intestinal obstruction [7, 9]. Most of the patients with solitary duodenal 
RCC metastasis present with gastrointestinal bleeding (69%), anemia and fatigue, whereas 
others present with early satiety, bowel obstruction, abdominal pain or jaundice from 
biliary obstruction [4, 7, 10, 11]. Patients post nephrectomy for RCC presenting with 
gastrointestinal symptoms should undergo complete diagnostic work-up with both 
endoscopic and radiologic evaluation, for detection and evaluation of the extent of 
metastatic disease. On endoscopy the lesion can be seen as a submucosal mass with 
ulceration of the tip, multiple nodules of varying sizes or raised plaques [12]. Endoscopic 
biopsy of suspicious lesions provides tissue for histologic diagnosis of metastasis and 
helps to distinguish primary gastrointestinal malignancy from metastatic disease.  
The treatment options in a case of solitary duodenal RCC metastasis depend upon 
the extent and location of the lesion and therapy must be individually tailored. 
Procedures ranging from classic pancreaticoduodenectomy (Whipple procedure) to 
interventional embolization have been reported (table 1). Any patient with solitary 
metastatic RCC to the duodenum should be considered a candidate for complete surgical 
excision if medically and technically feasible, both for palliation of symptoms and because  
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it provides the opportunity for meaningful disease-free survival. Therapeutic goals 
include complete metastatectomy whenever surgically feasible. A curative role for 
pancreaticoduodenectomy in patients with solitary duodenal metastasis has been reported 
and has been shown to improve survival [11, 13–16]. Hemostasis of gastrointestinal 
bleeding occurring due to metastasis or invasion of malignant tumor is hard to manage 
endoscopically, and data on endoscopic therapy of bleeding from these duodenal lesions 
are limited. In selected cases, intractable gastrointestinal bleeding can be treated with 
arterial embolization of tumor-supplying arteries that has been reported to control 
gastrointestinal bleeding effectively, but there are no long-term follow-up data [17–19]. 
However, embolotherapy is only palliative while the tumor develops other collateral 
vessels and has potential for re-bleeding [20]. Also, in these cases, the physician should 
keep in mind that embolization for control of hemorrhage in the small bowel carries a 
significant risk of bowel infarction. For disseminated malignancy, treatment is mainly 
supportive and palliative, in the form of palliative surgery, radiotherapy, chemotherapy or 
immune-stimulating agents (interleukin-2) [10, 21, 22]. Patients with metastatic disease 
have poor survival despite the above treatment. The average survival is about 4 months 
and only 10% of them survive for 1 year [23]. 
This case report highlights the importance of vigilance and high index of suspicion in 
post nephrectomy patients upon presentation of new clinical symptoms. Appropriate 
awareness, recognition and aggressive work-up of gastrointestinal symptoms in patients 
post nephrectomy for RCC are of paramount importance. 
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Table 1. Previously reported cases of solitary renal cell carcinoma metastatic to the duodenum/ampulla 
Authors Year  Age/ 
sex 
Duration 
post ne-
phrectomy 
(years) 
Location of 
metastasis 
Presenting symptoms  Treatment  Survival  
Rustagi et al. (current)  2011  66/M  13  duodenum  GI bleeding, fatigue,  
weight loss 
embolization and PPPD  2 weeks 
Adamo et al. [4]  2008  86/F  13  duodenum  anemia, early satiety  classic Whipple  7 months 
Bhatia et al. [10]  2006  50/M  01  duodenum  jaundice, abdominal mass  diagnostic only  – 
Arroyo et al. [24]  2005  75/F  13  duodenum  –  –  – 
Arroyo et al. [24]  2005  52/M  02 duodenum  –  –  5  months 
Loualidi et al. [6]  2004  76/M  05 duodenum  GI  bleeding  palliative  radiotherapy  – 
Pavlakis et al. [7]  2004  65/M  02  duodenum  obstruction  intestinal resection  9 months 
Sawh et al. [25]  2002  53/M  06  duodenum  GI bleeding  duodenectomy and embolization  4 years 
Nabi et al. [26]  2001  40/M  04  duodenum  obstruction with bilious  
vomiting, abdominal pain 
gastrojejunostomy 7  days 
Hashimoto et al. [27]  2001  57/M  11  duodenum  GI bleeding  PPPD  – 
Sohn et al. [14]  2001  0–/–  06 ampulla  –  classic  Whipple  22  months
Le Borgne et al. [13]  2000  48/M  13  duodenum  GI bleeding  classic Whipple  53 months
Le Borgne et al. [13]  2000  72/F  07  duodenum  GI bleeding  classic Whipple  18 months
Ohmura et al. [20]  2000  62/M  05 duodenum  obstruction  embolization and local resection  – 
Janzen et al. [3]  1998  75/M  17  ampulla  GI bleeding  duodenectomy, total 
pancreatectomy 
– 
Toh & Hale [11]  1996  59/F  10  duodenum  obstruction, abdominal pain, 
anemia 
duodenectomy, mass excision  – 
Gastaca Mateo et al. [28]  1996  48/M  08  duodenum  anemia, fatigue, weight loss  duodenectomy  3 years 
Leslie et al. [29]  1996  78/F  10  ampulla  GI bleeding, weight loss, 
abdominal discomfort,  
pruritus 
PPPD 30  months
Leslie et al. [29]  1996  53/M  08  ampulla  GI bleeding, weight loss  PPPD  78 months
Venu et al. [30]  1991  64/M  11  ampulla  GI bleeding, fatigue  –  – 
Robertson & Gertler [31]  1990  70/M  13  ampulla  GI bleeding  classic Whipple  – 
Lynch-Nyhan et al. [17]  1987  16/M  01  duodenum  GI bleeding  embolization  6 months 
Lynch-Nyhan et al. [17]  1987  61/M  06 duodenum  jaundice  embolization  – 
Lynch-Nyhan et al. [17]  1987  67/M  02 duodenum  GI  bleeding  –  – 
McNichols et al. [32]  1981  52/M  10  duodenum  malabsorption  diagnostic only  – 
Heymann & Vieta [9]  1978  64/M  08  duodenum  GI bleeding  complex procedure  3 weeks 
Tolia & Whitmore [33]  1975  0–/M 16  duodenum  –  –  5  months 
Lawson et al. [34]  1966  69/F  00  duodenum  GI bleeding, anemia  classic Whipple  8 months 
PPPD = Pylorus-preserving pancreaticoduodenectomy. 
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Fig. 1. Endoscopic image showing a 4 cm polypoidal mass in the second part of the duodenum. This 
mass was actively bleeding and appeared irregular, ulcerative and friable giving it a ‘malignant 
appearance’. 
 
 
 
Fig. 2. Computed tomography scan of the abdomen showing a 5.4 × 3.3 cm mass at the junction of the 
second and third part of the duodenum: axial view (a) and sagittal view (b). The mass is noted to be 
adjacent but not involving the head of the pancreas. No evidence of hepatic or visceral metastasis is seen 
and no lymphadenopathy is noted. 
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Fig. 3. Histopathology of the resected mass showing large polygonal clear cells arranged in a trabecular 
and alveolar pattern, yielding a diagnosis of RCC of clear cell type. 
 
 
 
Fig. 4. Immunohistochemical staining demonstrates clear cells positive for vimentin. Immunostaining 
was also positive for CD10, AE1/AE3 and epithelial membrane antigen and negative for CK7, CK20 or 
PNRA markers, confirming the diagnosis of RCC of clear cell type. 
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